RESUMEN
Background: Clinical observations and epidemiological studies suggest a potential linkage between gastroesophageal reflux disease (GERD) and arrhythmias, yet the underlying mechanism remains elusive. This study investigates the causal relationship between GERD and four types of arrhythmia through a genetic lens, employing Mendelian randomization analysis to elucidate the directionality of these associations. Methods: Selected single nucleotide polymorphisms (SNPs) from genome-wide association study (GWAS) data were utilized as instrumental variables. The inverse variance weighting (IVW) method, MR-Egger regression analysis, and the weighted median method were employed in two-sample Mendelian randomization analysis. Horizontal pleiotropy was detected and corrected using the MR-PRESSO test and MR-Egger regression. The stability and reliability of the Mendelian randomization results were assessed using the leave-one-out method, Cochran's Q test, and funnel plots. The causal relationship between GERD and four types of arrhythmias was evaluated using the odds ratio (OR). Results: IVW results indicated that GERD could increase the risk of arrhythmias. A one standard deviation increases in the logarithmically transformed GERD score resulted in a 34% increase in the risk of arrhythmia (OR = 1.34; 95% CI 1.19-1.51; p = 1.66E-06). No significant correlation was found between GERD and other arrhythmias. Conclusion: A causal relationship exists between GERD and arrhythmias, suggesting that GERD increases the risk of developing these arrhythmias.
RESUMEN
BACKGROUND: Dyslipidemia is one of the most popular metabolic diseases and an important risk factor for arteriosclerotic cardiovascular diseases. In China, Wendan decoction (WDD) has been widely used to treat hyperlipidemia. However, no systematic review has been found. In order to evaluate the efficacy and safety of WDD in the treatment of dyslipidemia, a meta-analysis and systematic evaluation are conducted. METHODS: The randomized controlled trials (RCTs) evaluating the effectiveness and safety of WDD in the treatment of dyslipidemia will be enrolled. Data are mainly from 4 English databases (Pubmed, Embase, Cochrane Library, and Web of science) and 4 Chinese databases (Wanfang, CBM, CNKI, and VIP Database). The enrollment of RCTs is from the starting date of database establishment till December 15, 2018. Low density lipoprotein cholesterol is considered as the main outcome, while the serum concentrations of total cholesterol, triglyceride, high density lipoprotein cholesterol, apolipoprotein A, and apolipoprotein B are regarded as the secondary outcome. Safety indicators include liver enzyme, fasting blood glucose, and kidney function. The work such as selection of literature, data collection, quality evaluation of included literature, and assessment of publication bias will be conducted by 2 independent researchers. Meta-analysis will be performed by RevMan 5.0 software. RESULTS: This study will provide high-quality evidence for the treatment of dyslipidemia with WDD in terms of effectiveness and safety. CONCLUSION: The results of the study will help us determine whether WDD can effectively treat hyperlipidemia. PROSPERO REGISTRATION NUMBER: PROSPERO CRD 42018114957.